Reviewing scPharmaceuticals Inc. (SCPH)’s and Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s results – MS Wkly

We are contrasting scPharmaceuticals Inc. (NASDAQ:SCPH) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us scPharmaceuticals Inc. and Sarepta Therapeutics Inc.s return on assets, return on equity and net margins.

Liquidity

scPharmaceuticals Inc. has a Current Ratio of 8.5 and a Quick Ratio of 8.5. Competitively, Sarepta Therapeutics Inc.s Current Ratio is 12.2 and has 11.1 Quick Ratio. Sarepta Therapeutics Inc.s better ability to pay short and long-term obligations than scPharmaceuticals Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for scPharmaceuticals Inc. and Sarepta Therapeutics Inc.

On the other hand, Sarepta Therapeutics Inc.s potential upside is 126.93% and its consensus target price is $189.44.

Institutional & Insider Ownership

scPharmaceuticals Inc. and Sarepta Therapeutics Inc. has shares owned by institutional investors as follows: 60.3% and 95.9%. Insiders owned 0.1% of scPharmaceuticals Inc. shares. Competitively, Sarepta Therapeutics Inc. has 0.3% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year scPharmaceuticals Inc.s stock price has bigger growth than Sarepta Therapeutics Inc.

Summary

Sarepta Therapeutics Inc. beats scPharmaceuticals Inc. on 6 of the 11 factors.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charleys Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the rest here:
Reviewing scPharmaceuticals Inc. (SCPH)'s and Sarepta Therapeutics Inc. (NASDAQ:SRPT)'s results - MS Wkly